Search | IOVS | ARVO Journals

iovs

Issues
Topics
For Authors
About
- Editorial Board

Journals Home

MANAGE ALERTS

Forgot password?

Create an Account

To View More...

Purchase this article with an account.

or

Subscribe Now

Issues
Topics
For Authors
About
- Editorial Board

Narrow View

NARROW

Content Type

Meeting Abstract (7)
Journal Articles (1)

Journal

Investigative Ophthalmology & Visual Science (8)

Article Type

ARVO Annual Meeting Abstract (7)
Physiology and Pharmacology (1)

Topics

Eye Anatomy and Disorders (1)
Glaucoma (1)

Tags

animal model (1)
cyclic gmp (1)
dog, domestic (1)
donors (1)
intraocular pressure (1)
nitric oxide (1)
ocular hypertension (1)
oryctolagus cuniculus (1)
primates (1)

Specify Date Range

From: To: Apply

Showing 1 – 8 of 8

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Physiology and Pharmacology March 2021

NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs

PDF

Elena Bastia; Carol B. Toris; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Michael V. W. Bergamini; Emanuela Masini; Silvia Sgambellone; Andrea M. Unser; Feryan Ahmed; Karen Y. Torrejon; Tomas Navratil; Francesco Impagnatiello
TAGS: animal model, dog, domestic, intraocular pressure, ocular hypertension, oryctolagus cuniculus, nitric oxide, primates, donors, cyclic gmp
Invest. Ophthalmol. Vis. Sci.. 2021; 62(3):17. doi: https://doi.org/10.1167/iovs.62.3.17

ARVO Annual Meeting Abstract June 2020

Intraocular pressure (IOP)-lowering effects of NCX 1770, a dual acting new chemical entity with nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitory properties in rabbit and non-human primate models of ocular hypertension and glaucoma

Elena Bastia; Carol Toris; Michael V W Bergamini; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Francesco Impagnatiello

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1232. doi:

ARVO Annual Meeting Abstract June 2020

Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma

Francesco Impagnatiello; Tomas Navratil; Carol Toris; Michael V W Bergamini; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Elena Bastia

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2786. doi:

ARVO Annual Meeting Abstract July 2019

Concomitant dosing of the NO-donor NCX 667 (1%) and Xalatan® (latanoprost ophthalmic solution 0.005%) results in robust and sustained IOP-lowering in ocular normotensive dogs

Michael V W Bergamini; Tomas Navratil; Francesco Impagnatiello; Elena Bastia

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3193. doi:

ARVO Annual Meeting Abstract July 2019

NCX 1741, a novel NO-donating derivative of the phosphodiesterase-5 inhibitor avanafil, reduces IOP in models of ocular hypertension and glaucoma

Francesco Impagnatiello; Elena Bastia; Carol B Toris; Shan Fan; Stefania Brambilla; Corinna Galli; Nicoletta Almirante; Michael V W Bergamini

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3770. doi:

ARVO Annual Meeting Abstract July 2019

Nonclinical development of NCX 470, a novel nitric oxide (NO)-donating,IOP lowering prostaglandin analog for glaucoma and ocular hypertension

Elena Bastia; Nicoletta Almirante; Michael V W Bergamini; Tomas Navratil; Marlene Woodruff Modi; Francesco Impagnatiello

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3806. doi:

ARVO Annual Meeting Abstract July 2019

Preclinical Evaluation of NCX 4251, a Novel Steroid Therapy for Blepharitis, Targeted Directly to the Eyelid Margin to Reduce the Potential for IOP Elevations

Tomas Navratil; Jean-Michel Bukowski; Frederic Pilotaz; Amanda Graves; Akshay Nadkarni; Amber Allen; Brigitte Duquesroix; Elena Bastia; Laura Storoni; Angela Kothe; Michael V W Bergamini; Jay Pennell; Brian G Short; Thomas Walters; Robert D Fechtner; Donald L Budenz

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6755. doi:

ARVO Annual Meeting Abstract June 2017

Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma

Elena Bastia; Francesco Impagnatiello; Ennio Ongini; Janet B Serle; Michael V W Bergamini

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2106. doi:

« Previous

Advertisement

Follow @ARVOiovs

IOVS Home
Issues
Topics
For Authors
About
- Editorial Board

Online ISSN: 1552-5783

Investigative Ophthalmology & Visual Science
Journal of Vision
Translational Vision Science & Technology

JOURNALS HOME
TOPICS
ABOUT ARVO JOURNALS

Copyright © 2015 Association for Research in Vision and Ophthalmology.

Forgot password?

To View More...

Purchase this article with an account.

Create an Account

or

Subscribe Now

×

×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept